A weekly cisplatin-based induction regimen for extensive non-small cell lung cancer: A Southwest Oncology Group study

C. S. Higano, Robert B Livingston, R. B. Livingston, J. W. Goodwin, B. Barlogie, W. J. Stuckey

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The purpose of this Phase II pilot study was to determine whether a dose-intensive regimen of weekly cisplatin combined with other active non-cross-resistant agents would improve the response rate and survival time of patients with extensive non-small cell lung cancer. Patients received cisplatin (50 mg/m2/wk) on days 1, 8, 15, 22, 36, 43, 50, and 57 combined with mitomycin C (8 mg/m2) on days 1 and 36, vinblastine (3 mg/m2) on days 8 and 43, and 5-fluorouracil (5-FU) (1 g/m2) by continuous infusion over 24 hours on days 15 and 50. Responding patients received consolidation therapy with cisplatin and etoposide (VP-16). Of 82 registered patients, 80 were eligible and 77 were evaluable for response. The overall response rate was 23% with 1 patient achieving a complete response (CR) and 17 patients achieving a partial response (PR). The median survival time was 4.6 months. The toxicity profile was not different from that described for standard-dose regimens. Although this regimen does not offer any benefit over standard-dose cisplatin regimens for patients with extensive non-small lung cancer, the weekly schedule permits a dose-intensive regimen with acceptable toxicity for tumors that may benefit from this approach.

Original languageEnglish (US)
Pages (from-to)2439-2442
Number of pages4
JournalCancer
Volume67
Issue number10
StatePublished - 1991
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Cisplatin
Etoposide
Vinblastine
Mitomycin
Fluorouracil
Lung Neoplasms
Appointments and Schedules
Survival Rate
Survival
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Higano, C. S., Livingston, R. B., Livingston, R. B., Goodwin, J. W., Barlogie, B., & Stuckey, W. J. (1991). A weekly cisplatin-based induction regimen for extensive non-small cell lung cancer: A Southwest Oncology Group study. Cancer, 67(10), 2439-2442.

A weekly cisplatin-based induction regimen for extensive non-small cell lung cancer : A Southwest Oncology Group study. / Higano, C. S.; Livingston, Robert B; Livingston, R. B.; Goodwin, J. W.; Barlogie, B.; Stuckey, W. J.

In: Cancer, Vol. 67, No. 10, 1991, p. 2439-2442.

Research output: Contribution to journalArticle

Higano, CS, Livingston, RB, Livingston, RB, Goodwin, JW, Barlogie, B & Stuckey, WJ 1991, 'A weekly cisplatin-based induction regimen for extensive non-small cell lung cancer: A Southwest Oncology Group study', Cancer, vol. 67, no. 10, pp. 2439-2442.
Higano, C. S. ; Livingston, Robert B ; Livingston, R. B. ; Goodwin, J. W. ; Barlogie, B. ; Stuckey, W. J. / A weekly cisplatin-based induction regimen for extensive non-small cell lung cancer : A Southwest Oncology Group study. In: Cancer. 1991 ; Vol. 67, No. 10. pp. 2439-2442.
@article{9d256dffeb1649d7bec7e69dc0ba77b8,
title = "A weekly cisplatin-based induction regimen for extensive non-small cell lung cancer: A Southwest Oncology Group study",
abstract = "The purpose of this Phase II pilot study was to determine whether a dose-intensive regimen of weekly cisplatin combined with other active non-cross-resistant agents would improve the response rate and survival time of patients with extensive non-small cell lung cancer. Patients received cisplatin (50 mg/m2/wk) on days 1, 8, 15, 22, 36, 43, 50, and 57 combined with mitomycin C (8 mg/m2) on days 1 and 36, vinblastine (3 mg/m2) on days 8 and 43, and 5-fluorouracil (5-FU) (1 g/m2) by continuous infusion over 24 hours on days 15 and 50. Responding patients received consolidation therapy with cisplatin and etoposide (VP-16). Of 82 registered patients, 80 were eligible and 77 were evaluable for response. The overall response rate was 23{\%} with 1 patient achieving a complete response (CR) and 17 patients achieving a partial response (PR). The median survival time was 4.6 months. The toxicity profile was not different from that described for standard-dose regimens. Although this regimen does not offer any benefit over standard-dose cisplatin regimens for patients with extensive non-small lung cancer, the weekly schedule permits a dose-intensive regimen with acceptable toxicity for tumors that may benefit from this approach.",
author = "Higano, {C. S.} and Livingston, {Robert B} and Livingston, {R. B.} and Goodwin, {J. W.} and B. Barlogie and Stuckey, {W. J.}",
year = "1991",
language = "English (US)",
volume = "67",
pages = "2439--2442",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - A weekly cisplatin-based induction regimen for extensive non-small cell lung cancer

T2 - A Southwest Oncology Group study

AU - Higano, C. S.

AU - Livingston, Robert B

AU - Livingston, R. B.

AU - Goodwin, J. W.

AU - Barlogie, B.

AU - Stuckey, W. J.

PY - 1991

Y1 - 1991

N2 - The purpose of this Phase II pilot study was to determine whether a dose-intensive regimen of weekly cisplatin combined with other active non-cross-resistant agents would improve the response rate and survival time of patients with extensive non-small cell lung cancer. Patients received cisplatin (50 mg/m2/wk) on days 1, 8, 15, 22, 36, 43, 50, and 57 combined with mitomycin C (8 mg/m2) on days 1 and 36, vinblastine (3 mg/m2) on days 8 and 43, and 5-fluorouracil (5-FU) (1 g/m2) by continuous infusion over 24 hours on days 15 and 50. Responding patients received consolidation therapy with cisplatin and etoposide (VP-16). Of 82 registered patients, 80 were eligible and 77 were evaluable for response. The overall response rate was 23% with 1 patient achieving a complete response (CR) and 17 patients achieving a partial response (PR). The median survival time was 4.6 months. The toxicity profile was not different from that described for standard-dose regimens. Although this regimen does not offer any benefit over standard-dose cisplatin regimens for patients with extensive non-small lung cancer, the weekly schedule permits a dose-intensive regimen with acceptable toxicity for tumors that may benefit from this approach.

AB - The purpose of this Phase II pilot study was to determine whether a dose-intensive regimen of weekly cisplatin combined with other active non-cross-resistant agents would improve the response rate and survival time of patients with extensive non-small cell lung cancer. Patients received cisplatin (50 mg/m2/wk) on days 1, 8, 15, 22, 36, 43, 50, and 57 combined with mitomycin C (8 mg/m2) on days 1 and 36, vinblastine (3 mg/m2) on days 8 and 43, and 5-fluorouracil (5-FU) (1 g/m2) by continuous infusion over 24 hours on days 15 and 50. Responding patients received consolidation therapy with cisplatin and etoposide (VP-16). Of 82 registered patients, 80 were eligible and 77 were evaluable for response. The overall response rate was 23% with 1 patient achieving a complete response (CR) and 17 patients achieving a partial response (PR). The median survival time was 4.6 months. The toxicity profile was not different from that described for standard-dose regimens. Although this regimen does not offer any benefit over standard-dose cisplatin regimens for patients with extensive non-small lung cancer, the weekly schedule permits a dose-intensive regimen with acceptable toxicity for tumors that may benefit from this approach.

UR - http://www.scopus.com/inward/record.url?scp=0025913142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025913142&partnerID=8YFLogxK

M3 - Article

C2 - 1849785

AN - SCOPUS:0025913142

VL - 67

SP - 2439

EP - 2442

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -